BioWorld Asia

July 19, 2006

Actelion, Roche Sign $630M Autoimmunity Product Deal

Shrugging off recent disappointments in the clinic, Actelion AG signed what is likely to be one of the landmark licensing deals in European biotechnology in 2006. (BioWorld International) Read More

DeCode Stock Sale To Raise $30M For Multidrug Pipeline

Motility Control Proteins Might Play Part In Pancreatic Cancer

Crucell Shares Fall After Aerugen Program Ended

ProStrakan Secures Deal, Raises £11M In Placement

Nasdaq In Lead, But Potential LSE Merger Raises Questions

Cellectis, Lexicon Genetics Exchange Rights To Patents

Devices In Past, Medisys Now Complete As Investing Firm

Advanced Therapies Under Scrutiny At EU Parliament

Astion Brings In DKK50M For Dermatology Pipeline

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 22, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...